Alvogen Acquires NAPRELAN® Tablets

Alvogen Pharma US, Inc. (“Alvogen”), the U.S. subsidiary of a
multinational pharmaceutical company, today announced it has finalized a
transaction with Shionogi Inc., acquiring the exclusive right to
commercialize NAPRELAN® (naproxen sodium) controlled-release tablets,
375 mg, 500 mg, and 750 mg, in the United States. The product will be
marketed by Almatica Pharma Inc., a subsidiary of Alvogen.

In a separate transaction, Alvogen also acquired all rights and interest
in the New Drug Application (“NDA”) for NAPRELAN® from Stat-Trade, Inc.
According to IMS Health data, NAPRELAN® had annual U.S. sales of $58
million in 2012.

”Alvogen’s acquisition of NAPRELAN® delivers on yet another strategic
objective by further strengthening and diversifying our growing branded
portfolio in the U.S. market,” said Darren Alkins, President, Alvogen

Alvogen is a multinational, privately-owned pharmaceuticals company,
focused on developing, manufacturing and distributing generic, brand,
over-the-counter brands (OTC) and biosimilar products. With more than
200 pharmaceutical projects in development and registration, the group’s
product portfolio consists of a broad range of leading molecules for the
treatment of conditions in the fields of oncology, cardiology,
respiratory, neurology and gastroenterology. Alvogen has commercial
operations in over 30 countries with 1,900 employees. North America is
Alvogen’s single largest market.

for further information on Naprelan® tablets.

NAPRELAN® is a registered trademark of Alvogen Pharma US, Inc.

Alvogen Pharma US, Inc.Alexander
Mironov, +1-973-487-3951Vice President, U.S. Business DevelopmentAlexander.Mironov@alvogen.comorHalldor Kristmannsson, +354 522 2928Vice
President, Organizational Development, Global Communications & Media

Source: Alvogen Pharma US, Inc.